Clinical trials: VZV
Herpes Zoster, Herpes Zoster Vaccine
Study to Evaluate Efficacy, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 70 Years and Older
The purpose of this observer-blind study is to evaluate the efficacy, safety and immunogenicity of GSK Biologicals' candidate Herpes Zoster (HZ) vaccine in adults aged ≥ 70 years.
- Trial name
- NCT01165229
- Testing
- Herpes Zoster Vaccine GSK1437173A
- Where
- 213 sites in United States, Australia and 16 more
- Volunteers
- 14,819 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Human Papilloma Virus (HPV), Tetanus-diphtheria-acellular Pertussis (Tdap)
Evaluation of Vaccination Reminder/Recall Systems for Adolescent Patients
A study team with extensive experience in immunization delivery research will evaluate the effectiveness of vaccination reminder/recall systems for adolescent patients in five types of clinical settings including: urban…
- Conditions
- Human Papilloma Virus (HPV), Tetanus-diphtheria-acellular Pertussis (Tdap), Meningococcal Infection, Varicella
- Trial name
- NCT00715234
- Testing
- Reminder/recall notices for vaccines
- Volunteers
- 4,807 people
- Sponsor
- University of Colorado, Denver
Chicken-pox Illness (Varicella Virus Disease), Chickenpox
A Safety and Immune Study of 2 Types of GlaxoSmithKline's Varicella Vaccines Given as a 2-doses Course to Healthy Children 12-23 Months of Age.
The purpose of this study is to evaluate the safety and immunogenicity of 2 formulations of GSK Biologicals' varicella vaccines given as a 2-dose course in the second year of life.
- Trial name
- NCT02570126
- Testing
- Varilrix HSA-free, Varilrix™
- Where
- 23 sites in Estonia, Germany and 3 more
- Volunteers
- 1,236 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Varicella
Immunogenicity and Safety of NBP608 Compared to Varivax in Healthy Children 12 Months to 12 Years of Age
This study assesses non-inferiority by comparing seroconversion rate of NBP608 to Varivax which are indicated for active immunization for prevention of varicella.
- Trial name
- NCT03114943
- Testing
- NBP608, Varivax
- Where
- Philippines
- Volunteers
- 516 people, healthy volunteers welcome
- Sponsor
- SK Bioscience Co., Ltd.
Post Herpetic Neuralgia
Phase IV Study of FDA Approved, Once-Daily GRALISE™(Gabapentin) Tablets for the Treatment of Postherpetic Neuralgia
Study objective is to assess the safety and effectiveness of once- daily GRALISE in clinical practice
- Trial name
- NCT01426230
- Where
- 37 sites in United States
- Volunteers
- 201 people
- Sponsor
- Depomed
Herpes Zoster
A Study to Assess the Burden of Herpes Zoster and Postherpetic Neuralgia in Japanese Adults Aged Sixty Years and Above
The study aims to estimate the incidence of herpes zoster (HZ), proportion of postherpetic neuralgia (PHN) and the economic burden and impact on quality of life, in Japanese adults greater than or equal to sixty years of age.
- Trial name
- NCT01873365
- Testing
- Data collection
- Where
- 14 sites in Japan
- Volunteers
- 448 people
- Sponsor
- GlaxoSmithKline
Infectious Disease, Pneumonia, Bacterial
Vaccination Education Through Pharmacists and Senior Centers (VEPSC)
The study consists of two arms (PHARM and PEER) designed to educate participants about three vaccine-preventable diseases (zoster, pneumonia, and influenza) and vaccination.
- Conditions
- Infectious Disease, Pneumonia, Bacterial, Influenza, Zoster; Herpes
- Trial name
- VEPSC (NCT03239665)
- Testing
- Pharmacist-led Intervention (PHARM), Peer-led Intervention (PEER)
- Where
- United States
- Volunteers
- 335 people, healthy volunteers welcome
- Sponsor
- Rutgers, The State University of New Jersey
Mumps, Rubella
Immunogenicity, Safety of Measles-mumps-rubella-varicella Vaccine (MeMuRu-OKA) Compared to Priorix™ Given With Varilrix™
Since measles-mumps-rubella (MMR) and varicella vaccinations are established as routine childhood practice and often co-administered during the second year of life, a combined measles-mumps-rubella-varicella (MeMuRu-OKA) vaccine…
- Conditions
- Mumps, Rubella, Measles, Varicella
- Trial name
- NCT00352898
- Testing
- MeMuRu-OKA (study vac), MMR, Varicella vacc (control)
- Where
- 6 sites in Canada, Italy
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Varicella, Herpes Zoster
A Study to Evaluate Long-term Impact of VARIVAX Among Children and Adolescents (V210-036)(COMPLETED)
The purpose of these continuing post-licensure studies is to evaluate the long-term effectiveness of VARIVAX® [Varicella Virus Vaccine Live (Oka/Merck)] and to assess the impact of the vaccine on the epidemiology of varicella and…
- Trial name
- NCT01077804
- Volunteers
- 7,585 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Herpes Zoster
Immunogenicity and Safety of NBP608 Compared to Zostavax in Healthy Adult Aged 50 and Over
This study assesses non-inferiority by comparing GMR(Geometric Mean Ratio) of NBP608 to Zostavax which are evaluated by gpELISA (Glycoprotein Enzyme Linked Immunosorbent Assay).
- Trial name
- NCT03120364
- Testing
- NBP608, Zostavax
- Where
- South Korea
- Volunteers
- 824 people, healthy volunteers welcome
- Sponsor
- SK Chemicals Co., Ltd.
HIV Infections, Chickenpox
A Study of BV-araU in the Treatment of Varicella-Zoster Viral Disease (VZV) in HIV-Infected Children Who Have Not Had Success With or Who Cannot Take Other Treatments for VZV
To provide oral sorivudine ( BV-araU ) to pediatric HIV-infected patients with varicella-zoster viral disease who have failed or are intolerant of alternative therapy.
- Trial name
- NCT00002358
- Testing
- Sorivudine
- Where
- United States
- Sponsor
- Bristol-Myers Squibb
Herpes Zoster
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Recombinant Herpes Zoster Vaccine
The purposes of the study are to evaluate the Safety, Tolerability, and Immunogenicity of different dose levels of recombinant herpes zoster vaccine with 2 doses 60 days apart in healthy subjects aged 40 years and older.
- Trial name
- NCT06801509
- Testing
- Recombinant Herpes Zoster Vaccine (SCTV04C) Low-Dose, Recombinant Herpes Zoster Vaccine (SCTV04C) High-Dose, Shingrix®
- Where
- China
- Volunteers
- 540 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
Systemic Lupus Erythematosus
Safety of the Herpes Zoster Subunit Vaccine in Lupus
This randomized, double-blind, placebo-controlled, non-inferiority crossover study will evaluate the Herpes Zoster Sunbit (HZ/su) vaccine in SLE patients in order to evaluate safety and immunogenicity in patients with variable…
- Trial name
- NCT05559671
- Testing
- Herpes Zoster Subunit (HZ/su) Vaccine
- Where
- 2 sites in United States
- Volunteers
- 224 people
- Sponsor
- NYU Langone Health
Herpes Zoster
Persistence of Protection by Shingrix
The study plans to learn more about how the shingles vaccine, Shingrix (SRX), successfully prevents shingles in older people. Two vaccines are currently approved by the Food and Drug Administration (FDA) to prevent shingles.
- Trial name
- NCT04169009
- Testing
- Zostavax, Shingrix
- Where
- United States
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Chickenpox, Zoster
Safety and Immunogenicity Study of Live Attenuated Vaccine Against Varicella Without Gelatin
The purpose of this study is to observe the occurrence of adverse reaction and antibody positive rate, the elevated level of antibody，Geometric mean titer (GMT) between groups of live attenuated varicella vaccine without gelatin.
- Trial name
- NCT01684072
- Testing
- vaccine without gelatin, vaccine with gelatin
- Where
- 3 sites in China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Beijing Center for Disease Control and Prevention
Neuralgia, Herpes Zoster
Development of a Bedside Pain Assessment Kit for Postherpetic Neuralgia
Post herpetic neuralgia (PHN) is an undertreated condition. It is a type of neuropathic pain (NP), or pain caused by abnormal activity of sensory nerves.
- Trial name
- BSTK (NCT01166295)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Analgesic Solutions
Varicella-zoster Virus
Phase II Clinical Trial of Lyophilized Herpes Zoster mRNA Vaccine in Adults Aged 40 Years or Above
The primary objective of this study is to evaluate the immunogenicity and safety of 2 injections (approximately 2 months apart) of ABO1108 in adults aged 40 years or above.
- Trial name
- NCT07285278
- Testing
- ABO1108
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Suzhou Abogen Biosciences Co., Ltd.
Shingles
Safety, Tolerability, and the Body's Ability to Develop Resistance to an Investigational Vaccine for Shingles (V211-007)
The purpose of this study is to determine the immunity (the body's protection) against shingles after receiving two doses of an investigational vaccine or placebo (a look alike vaccine with no active ingredients).
- Trial name
- NCT00109122
- Testing
- zoster vaccine live (Oka/Merck)
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Measles, Mumps
Safety, Tolerability, and Immunogenicity of 3 Frozen ProQuad Consistency Lots in Healthy Children (V221-012)(COMPLETED)
This study will compare three consistency lots of ProQuad to each other as well as to M-M-R II and Varivax, administered concomitantly at different injection sites, with respect to immunogenicity, safety, and tolerability.
- Conditions
- Measles, Mumps, Rubella, Varicella
- Trial name
- NCT00985153
- Testing
- Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live, Comparator: Varivax, Comparator: M-M-R II
- Volunteers
- 3,927 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
VZV, Varicella Immunisation
Study on Booster Immunization With Varicella Vaccine at Different Intervals
The goal of this clinical trial is to evaluate the immunogenicity and safety of booster immunization of varicella live attenuated vaccine (varicella vaccine hereafter) at different intervals.
- Trial name
- NCT06994052
- Testing
- Varicella vaccine
- Where
- China
- Volunteers
- 412 people, healthy volunteers welcome
- Sponsor
- Sinovac (Dalian) Vaccine Technology Co., Ltd.